Medical_Devices — European UPC Patent Cases
225 decisions indexed
Page 7 of 8 · 225 total
Meril Italy Srl v.Edwards Lifesciences Corporation
This UPC Court of Appeal decision addressed requests for the expedition of appeals concerning the validity of European patent EP 3 646 825, which relates to a prosthetic heart valve. The court ultimately rejected Meril's pleas for an expedited timeline. The ruling reinforces that procedural concerns regarding potential injunction risks must be managed through existing mechanisms within the UPC, rather than solely relying on accelerated timetables.
Meril Italy Srl v.Edwards Lifesciences Corporation
This procedural order from the UPC Court of Appeal addressed requests for expedition in multiple appeals concerning EP 3 646 825, a patent covering a prosthetic heart valve. The court ultimately rejected Meril's pleas to accelerate the proceedings, citing that existing legal mechanisms could manage the risks associated with pending validity challenges. This decision reinforces the standard procedural timetable of the UPC unless exceptional circumstances are met.
Advanced Bionics AG v.MED-EL Elektromedizinische Geräte Gesellschaft m.b.H.
This appeal decision addresses a critical procedural issue regarding jurisdiction within the Unified Patent Court (UPC). Advanced Bionics sought to transfer an infringement case to the Central Board to coordinate proceedings with a parallel revocation action. The UPC Appeals Board rejected this request, emphasizing that Article 33 of the EPC mandates party consent for such a jurisdictional shift. This ruling reinforces the strict adherence to procedural rules over convenience in managing complex litigation.
Bioletic Holding GmbH & Co. KG v.Light Guide Optics Germany GmbH; S.I.A. LIGHTGUIDE International
Bioletic Holding GmbH & Co. KG sought provisional measures against Light Guide Optics Germany GmbH and S.I.A. LIGHTGUIDE International, alleging that their product infringed on EP 3 685 783 B1 related to laser fibers for vein treatment. The Düsseldorf Local Division ultimately denied the request for an injunction. The court found that the claimant did not meet the necessary threshold of demonstrating exceptional harm or irreparable damage required for provisional relief, despite the long-standing competition.
Advanced Bionics AG v.MED-EL Elektromedizinische Geräte Gesellschaft m.b.H.
This UPC Board of Appeal decision addressed an application by Advanced Bionics to change the proceedings language from German to English, matching the patent's language. The court ultimately denied the request, emphasizing that while factors like industry standard language (English) and the patent language are considered, they do not override considerations such as parties' domicile and existing procedural arrangements. This case reinforces the UPC's discretionary approach to language changes, requiring a careful balancing of interests rather than relying solely on technical or commercial convenience.
A. Menarini Diagnostics s.r.l. v.Insulet Corporation
In a procedural order concerning provisional measures, the UPC addressed a request for confidentiality protection. The Court granted access restrictions on specific technical and business information submitted by A. Menarini Diagnostics s.r.l., classifying it as confidential. While rejecting the defendant's motion that all highlighted portions were secret, the ruling established strict rules governing who could view this sensitive data. This decision reinforces the UPC's commitment to balancing urgent proceedings with robust protection of proprietary information.
Edwards Lifesciences Corporation v.Meril Life Sciences Pvt Limited
In this procedural order, the UPC dismissed a request by multiple defendants for security for legal costs against the US-based claimant. The Court emphasized that while protecting defendants is important, it cannot unduly restrict a claimant's right to an effective remedy. The ruling clarified that the mere fact of being non-EU based is insufficient grounds for imposing security if the claimant demonstrates financial capacity and willingness to cover adverse costs.
Edwards Lifesciences Corporation v.Meril Lifesciences PVT Limited, Meril GmbH, Smis International OÜ, Sormedica UAB
This procedural order addresses the resumption of a complex infringement and revocation action after the UPC proceedings were stayed pending a decision from the EPO Boards of Appeal (TBA). The Court established a tailored timetable, granting the claimant 14 days to file an amended statement of claim and the defendants 42 days to respond with their amended defense and counterclaim for revocation. This ruling highlights the UPC's flexibility in managing procedural timelines when external decisions significantly alter the scope of the patent-in-suit.
Abbott Diabetes Care Inc. v.Dexcom Deutschland GmbH, Dexcom International Limited , Dexcom Inc.
In a procedural order concerning confidential information, the UPC Local Division Munich balanced the need for parties' effective legal representation against the protection of trade secrets. The Court granted the Defendants' request to classify certain internal documents as strictly confidential, limiting access only to named representatives and employees. This ruling reinforces the principle that while lawyers require necessary access, accountability must be maintained by clearly defining who is responsible for maintaining confidentiality.
DexCom, Inc. v.Abbott Scandinavia Aktiebolag et al.
In a significant decision, the UPC Local Division in Munich revoked EP 3 797 685 B1 during an infringement action brought by DexCom against Abbott. The patent covered communication systems for analyte monitoring devices, specifically glucose monitors like FreeStyle Libre 2. Because the patent was found to be invalid and subsequently revoked, the Court dismissed all claims of infringement. This case underscores the critical importance of concurrent revocation proceedings in UPC litigation.
Abbott Diabetes Care Inc. v.Dexcom Inc.
This procedural order addressed Abbott Diabetes Care Inc.'s request for the UPC to compel Dexcom entities to disclose the entire distribution chain of their G6 and G7 diabetes monitoring systems. The Court ruled that while such information can be requested during proceedings, Abbott's specific demand was disproportionate. The judge found that because Abbott had targeted only certain distributors, requesting the full global supply chain was not reasonably necessary for advancing its case.
CEAD B.V. v.BEGO Medical GmbH
This UPC decision addressed a motion concerning the confidentiality of litigation costs in a revocation action (UPC_CFI_367/2023). The parties sought to restrict access to detailed cost breakdowns, which included individually negotiated attorney fees. The Court ultimately granted public confidentiality for these documents, finding that the private interest in protecting fee arrangements outweighed the general public's need for such granular financial detail. This ruling reinforces the protection of sensitive commercial information within UPC proceedings.
Edwards Lifesciences Corporation v.Meril GmbH, Meril Life Sciences Pvt. Ltd., Meril Italy S.r.l.
This UPC decision addresses procedural scheduling in an infringement case involving Edwards Lifesciences and Meril. The court faced significant logistical challenges due to the unavailability of key defense counsel, who were tied up with other major litigation matters. After balancing efficiency goals against the right to fair representation, the Court set the interim conference for 2024 and scheduled the main oral hearing for 2025.
Powell Gilbert LLP v.Abbott Diabetes Care Inc.
This procedural order addressed a request by Powell Gilbert LLP for public access to the written pleadings and evidence in an ongoing UPC case involving Abbott Diabetes Care Inc. The Court ruled that once a decision has been rendered, the general interest of the public in scrutinizing court proceedings outweighs the parties' concern over maintaining procedural integrity, even if an appeal is pending. This reinforces the principle that transparency prevails after a judgment, setting a clear precedent for post-decision document access requests.
Powell Gilbert LLP v.Abbott Diabetes Care Inc.
This UPC decision addressed a request for public access to court documents following the conclusion of provisional measures proceedings. The Court ruled in favor of the applicant, Powell Gilbert LLP, granting access to pleadings and evidence. The ruling established that after a final decision is rendered, the general interest of the public in scrutinizing judicial decisions outweighs the parties' concerns regarding procedural integrity, even if an appeal is pending.
Abbott Diabetes Care Inc. v.Sibio Technology Limited; Umedwings Netherlands B.V.
In this procedural order, the UPC Court of Appeal addressed requests concerning auxiliary claims and deadlines in a provisional measures appeal involving Abbott Diabetes Care Inc. against Sibio Technology Limited and Umedwings Netherlands B.V. The court ultimately rejected Abbott's attempts to disregard the Respondents' request for an extension of time. This decision highlights the court's careful balancing act between parties' interests, particularly when new procedural requests are introduced late in proceedings.
Roche Diabetes Care GmbH v.Tandem Diabetes Care Inc.
This UPC decision addressed a procedural application to change the language of proceedings from German to English for an infringement case involving drug infusion systems. The Court ruled that despite one defendant being based in Germany, the interests and positions of the defendants collectively justified switching the language to English, which was the patent's granting language. This ruling reinforces the principle that when balancing linguistic interests, the position of the defendants holds decisive weight.
Meril Italy Srl v.Edwards Lifesciences Corporation
In a significant UPC decision, the Central Division rejected revocation actions against Edwards Lifesciences Corporation concerning its prosthetic heart valve patent (EP '825). The claimants argued for invalidity based on lack of novelty and inventive step. However, the Court maintained the patent's validity after accepting an amendment submitted by the defendant, underscoring the importance of procedural compliance in UPC litigation.
Meril Italy Srl v.Edwards Lifesciences Corporation
In a complex revocation action, the UPC Central Division rejected Meril Italy Srl's attempt to invalidate EP 3 646 825. The patent relates to an advanced prosthetic heart valve with a unique hexagonal cell frame design. Despite multiple procedural maneuvers and consolidation of related counterclaims, the Court upheld the patent's validity after incorporating amendments. This case underscores the UPC's jurisdiction over complex medical device patents and its strict approach to maintaining patent rights unless clear invalidity grounds are established.
Meril Italy Srl v.Edwards Lifesciences Corporation
In a significant decision concerning medical device patents, the UPC Central Division rejected revocation actions against EP '825. The patent relates to an advanced prosthetic heart valve with a unique hexagonal cell frame structure designed to prevent leakage. Although Meril Italy Srl initiated the action based on novelty and inventive step arguments, the Court ultimately maintained the patent's validity after considering amendments submitted by Edwards Lifesciences Corporation. This case highlights how procedural conduct, specifically the submission of limitations during proceedings, can determine the outcome of a revocation suit.
MED-EL Elektromedizinische Geräte Gesellschaft m.b.H. v.Advanced Bionics AG, Advanced Bionics GmbH, Advanced Bionics Sarl
In this UPC case concerning infringement of EP4074373, the Local Division decided to refer the revocation counterclaim and the claimant's request for patent amendment to the Central Division in Paris. This decision was based on procedural efficiency, as the core arguments against the patent were already being litigated in a prior central action initiated by one of the defendants. The court ruled that maintaining parallel proceedings would violate the principle of process economy.
DexCom, Inc. v.Abbott Scandinavia Aktiebolag, Abbott NV / SA, Abbott S.r.l., Abbott Diabetes Care Inc., Abbott Diagnostics GmbH, Abbott France, Abbott B.V., Abbott Logistics B.V., Abbott GmbH, Abbott Laboratories
In a significant ruling, the UPC Paris Local Division revoked European Patent EP3435866, which covers an analyte monitoring system used in Continuous Glucose Monitoring (CGM). The revocation was granted following a counterclaim by Abbott against DexCom. Consequently, all of DexCom's infringement claims were dismissed. This decision underscores the robust nature of the UPC's jurisdiction over validity challenges and confirms that the claimant cannot unilaterally prevent a defendant from challenging patent validity.
Abbott Diabetes Care Inc. v.SIBIO TECHNOLOGY LIMITED; UMEDWINGS NETHERLANDS B.V.
This UPC decision confirms a settlement reached in an application for provisional measures concerning EP 2 393 417 B1, which covers analyte sensors. The settlement mandates that the Defendants cease offering the infringing products in Germany, France, and the Netherlands, destroy existing stock, recall products from distribution channels, and compensate the Applicant for all damages on the merits. This case highlights how parties can resolve complex infringement disputes early through negotiated settlements within the UPC framework.
Franz Kaldewei GmbH & Co. KG v.Bette GmbH & Co. KG
This UPC decision addressed an infringement action brought by Franz Kaldewei against Bette GmbH & Co. KG concerning a sanitary bathtub installation protected by EP 3 375 337 B1. The court found the respondent liable for infringing the patent in several member states, ordering preliminary damages of EUR 10,000.00. However, the overall claims were partially dismissed, resulting in a mixed outcome regarding liability and costs.
Tandem Diabetes Care, Inc. v.Roche Diabetes Care GmbH
This procedural order in the UPC case involving Roche Diabetes Care GmbH and Tandem Diabetes Care, Inc. addressed a request for an extension of time to file a rejoinder in revocation proceedings. The Court ultimately denied the request, emphasizing that while flexibility is key in UPC procedure, extensions must be based on objective impossibility or extreme difficulty. This ruling reinforces the strict standard required for procedural relief, particularly when parties introduce new evidence.
Abbott Diabetes Care Inc. v.Sibio Technology Limited
In a provisional measures case concerning an on-body glucose sensor device (EP3831283), the UPC Court of First Instance denied the application filed by Abbott Diabetes Care Inc. The core finding was that the patent likely suffers from 'added matter,' making it probable that the claims would be invalidated during full proceedings. This decision not only blocked the preliminary injunction but also mandated that the applicant bear the costs of the current proceedings.
Abbott Diabetes Care Inc. v.Sibio Technology Limited
Abbott Diabetes Care Inc. successfully obtained a preliminary injunction against Sibio Technology Limited and Umedwings Netherlands B.V. regarding its CGM patent (EP2713879). The UPC Local Division granted the provisional measures, finding sufficient interest in the case despite initial objections from the defendants. This ruling is highly significant for medical device IP holders, demonstrating the court's willingness to grant immediate relief based on a cease-and-desist declaration when the application has legitimate purpose.
Abbott Diabetes Care Inc. v.Sibio Technology Limited
In this provisional measures case concerning an on-body glucose sensor device, the UPC Court of First Instance denied the preliminary injunction sought by Abbott Diabetes Care Inc. The core finding was that the patent in question (EP3831283) suffered from 'added matter,' making it highly probable that the patent would be invalidated if the full merits proceedings were held. This decision underscores the critical importance of strict adherence to the scope of claims during prosecution and litigation within the UPC framework.
Abbott Diabetes Care Inc. v.Sibio Technology Limited
Abbott Diabetes Care Inc. sought provisional measures against Sibio Technology Limited and Umedwings Netherlands B.V. regarding the alleged infringement of its CGM device patent (EP2713879) by the GS1 device. The UPC Local Division granted a preliminary injunction, immediately prohibiting the defendants from offering or placing the infringing product on the market in the relevant member states. This ruling is significant as it demonstrates the court's willingness to grant urgent relief based on sufficient interest, even when facing initial objections.
Tandem Diabetes Care, Inc., Tandem Diabetes Care Europe B.V. v.Roche Diabetes Care GmbH
In a preliminary objection hearing, the UPC Central Division addressed arguments concerning whether a standstill agreement could prevent the Court from exercising jurisdiction. The court ruled decisively that violating such an agreement does not equate to a lack of jurisdiction. This ruling clarifies the scope of contractual limitations on judicial proceedings within the UPC framework, emphasizing that procedural agreements cannot override the fundamental ability of the court to hear the case.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.